deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
The first gene silencing approach to Alzheimer's disease is reported, with a drug called BIIB080 used on the microtubule-associated protein tau (MAPT) gene. Patients in a Phase 1 trial were found to have a greater than 50% reduction in levels of harmful tau protein after taking the drug. 26 April Astronomers present an image, for the first time viewed together, of the shadow of the black hole in the center of the Messier 87 galaxy, and its related high-energy jet. The first global assessment of glacier mass loss from satellite radar altimetry is published. It shows that glaciers lost 2,720 gigatonnes of ice, about 2% of their volume, between 2010 and 2020. 28 April – Progress in AI software: ChatGPT is shown to outperform human doctors in responding to online medical questions when measured on quality and empathy by "a team of licensed health care professionals", albeit the chatbot may have previously been trained with these reddit question and answers threads.
==== Diagnosis ==== A bone mineral density test, such as dual-energy X-ray absorptiometry, is commonly used to assess bone strength, particularly in the hip and spine. Screening is generally recommended for women aged 65 and older, postmenopausal women with risk factors, and some men based on clinical evaluation.
Potassium, in the form of potassium chloride is used as a medication to treat and prevent low blood potassium. Low blood potassium may occur due to vomiting, diarrhea, or certain medications. It is given by slow injection into a vein or by mouth.
SpyTag and SpyCatcher were formed from the splitting and engineering of the CnaB2 domain of the FbaB protein from Streptococcus pyogenes, which naturally forms an intramolecular isopeptide bond to assist colonization of the host cell. With the formation of the isopeptide bond, the CnaB2 domain becomes more tolerant to conformational, thermal and pH changes. Building upon this, SpyTag was obtained from CnaB2 by extracting the C-terminal beta strand containing the reactive aspartic acid at D556 and leaving the rest of the beta strands containing the reactive lysine K470 and the catalytic glutamic acid at E516 to become SpyCatcher, after further engineering to remove some hydrophobic surface residues. The resulting SpyTag/SpyCatcher can react to form the isopeptide bond with a second-order rate constant of 1.4 ± 0.4 × 103 M−1 s−1. It is postulated that the reaction mechanism proceeds by a nucleophilic attack on D556 from K470, mediated by E516. By reconstituting SpyTag:SpyCatcher, the resulting conjugated complex acquires the stability of the parent CnaB2 domain. A second generation SpyTag/SpyCatcher called SpyTag002/SpyCatcher002 was then created through phage display that enables the peptide-protein pair to react up to 12 times faster than the original pair, at a rate constant of 2.0 ± 0.2 × 104 M−1 s−1. The second generation SpyCatcher002 also has abolished self-reactivity that is present with SpyCatcher. A third generation SpyTag/SpyCatcher called SpyTag003/SpyCatcher003 has now also been created through rational design.
=== Effects on insulin resistance === In all animal models of insulin resistance, moxonidine had striking effects on the development of insulin resistance, hyperinsulinaemia and impaired glucose homeostasis. Given the importance of insulin resistance as a risk factor for cardiovascular disease, it is of considerable relevance that it has been shown to improve insulin sensitivity.
Sources: en.wikipedia.org
=== Reasons for the development of multicellularity === Despite the fact that prokaryotic cells contained the building blocks required for multicellularity to arise, this transition did not occur for around 1500 million years after the origins of the first eukaryotic cell. Scientists have proposed two major theories for the reason that multicellularity arose so late after the appearance of life on Earth.
=== Sex-work and HIV === Despite the depth of knowledge of HIV/AIDS, rapid transmission has occurred globally in sex workers. The relationship between these two variables greatly increases the risk of transmission among these populations, and also to anyone associated with them, such as their sexual partners, their children, and eventually the population at large. Many street-level harm-reduction strategies have succeeded in reducing HIV transmission in injecting drug users and sex-workers. HIV education, HIV testing, condom use, and safer-sex negotiation greatly decreases the risk to the disease. Peer education as a harm reduction strategy has especially reduced the risk of HIV infection, such as in Chad, where this method was the most cost-effective per infection prevented. Decriminalisation as a harm-reduction strategy gives the ability to treat substance use disorder solely as a public health issue rather than a criminal activity. This enables other harm-reduction strategies to be employed, which results in a lower incidence of HIV infection. One of the first harm reduction models was called the "Mersey Harm Reduction Model" in 1980s Liverpool, and the success of utilizing outreach workers, distribution of education, and providing clean equipment to drug users was shown in the fact that an HIV epidemic did not happen in Mersey. The AIDS epidemic, which began in the 80s and peaked in 1995, further complicated the politicization of drug users and drug use in the US.
== Early life and education == Shaw was born in South Boston, and also grew up in Brookline, Massachusetts. Her mother was from South Boston. Shaw's parents divorced when she was four years old. She grew up in a single-mother home with an older half-brother, who owns a bar in Boston. Shaw attended Michael Driscoll School and Brookline High School. At Michael Driscoll, Shaw played full court streetball at a nearby neighborhood park. Shaw said that basketball was a constant of her childhood, and she incorporated it into the pilot and third episode of SMILF. After receiving a scholarship in her junior year, Shaw transferred to the private school Milton Academy in Milton, Massachusetts, where she graduated in 2000. In 2007, she graduated from Barnard College with a degree in literature.
=== Early ventures === Johnson launched three startups between 1999 and 2003. The first one sold cell phones and helped pay his way through Brigham Young University. Johnson hired other university students to sell service plans and cell phones; Johnson earned about a $300 commission on each sale. He also started two other businesses. Inquist, a VoIP company Johnson co-founded with three other partners, combined features of Vonage and Skype. It ended operations in 2001. After that, he joined his brother and another partner on a $70 million real estate project in 2001. The project did not meet its sales goals.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Different techniques detect different classes of impurities, so a single number does not describe a sample completely. Reversed-phase chromatography resolves related peptides well but can miss inorganic salts, while mass spectrometry confirms mass without quantifying everything present. Comparing results requires knowing which method was used and how it was validated.